BioCorRx (BICX) AI Stock Analysis

• Market Cap: $8.29M
• Dividend Yield: N/A
• Average Volume (3M): 806.00
• Price to Earnings (P/E): ―
• Beta (1Y): 0.50
• Revenue Growth: 3464.86%
• EPS Growth: 38.01%
• Country: US
• Employees: 3
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Care Facilities
• EPS (TTM): -0.07
• Shares Outstanding: 23,685,343
• 10 Day Avg. Volume: 1,260
• 30 Day Avg. Volume: 806
• PEG Ratio: -0.09
• Price to Book (P/B): -0.33
• Price to Sales (P/S): 518.78
• P/FCF Ratio: -3.63
• Enterprise Value/Market Cap: 1.60
• Enterprise Value/Revenue: 13.12
• Enterprise Value/Gross Profit: 38.95
• Enterprise Value/Ebitda: -4.55
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): -0.25
• Revenue Forecast (FY): $696.30K

• Rating: 28 Underperform
• Price Target: ―

BioCorRx's overall stock score is significantly impacted by its weak financial performance, characterized by declining revenues, high leverage, and negative cash flows. Technical analysis provides a slight positive note with signs of potential upward momentum, but the valuation remains a major concern due to negative profitability metrics. The absence of earnings call data and corporate events further emphasizes the need for a strategic turnaround.

Positive Factors

Innovative Product Offering

The proprietary implantable naltrexone pellet positions BioCorRx as an innovator in addiction treatment, potentially driving long-term demand and market differentiation.

Comprehensive Recovery Program

Offering a holistic recovery program enhances BioCorRx's value proposition, potentially increasing adoption by treatment centers and expanding revenue opportunities.

Partnership Opportunities

Strategic partnerships with medical facilities can expand BioCorRx's market reach and distribution, supporting sustainable revenue growth and market penetration.

Negative Factors

Declining Revenues

Consistent revenue decline indicates challenges in market demand or competitive positioning, potentially impacting long-term financial health and growth prospects.

High Leverage

High leverage and negative equity highlight financial instability, limiting BioCorRx's ability to invest in growth initiatives and increasing financial risk.

Negative Cash Flow

Negative operating cash flow indicates poor cash generation from core activities, constraining BioCorRx's operational flexibility and ability to fund future growth.

BioCorRx Business Overview & Revenue Model

Company Description

BioCorRx Inc. is a healthcare solutions company operating primarily in the substance use disorder treatment sector. The company offers a range of products and services aimed at combating addiction, including a proprietary implantable naltrexone pellet for alcohol and opioid use disorders. Their offerings are designed to support individuals in their recovery journey through a combination of medical intervention and behavioral therapy programs.

How the Company Makes Money

BioCorRx Inc. generates revenue through the sale of its addiction treatment products, particularly its naltrexone implant, which is distributed to healthcare providers and clinics specializing in addiction treatment. The company also makes money by offering a comprehensive recovery program that includes counseling and support services, which can be sold directly to treatment centers or licensed as a package. Additionally, BioCorRx may engage in partnerships with medical facilities and practitioners to expand the reach of its programs and products, contributing to its revenue streams.

BioCorRx Financial Statement Overview

Summary

BioCorRx is facing significant financial challenges, with declining revenues, consistent losses, high leverage, and negative cash flows. The company's financial health is weak, indicating an urgent need for a strategic turnaround to improve its financial position.

Income Statement

BioCorRx's revenue has declined significantly from 2020 to 2024, with a noticeable drop in 2024. Both EBIT and EBITDA margins are deeply negative, indicating operational inefficiencies and financial distress. Net profit margins are also negative, showing consistent losses over the years.

Balance Sheet

The company has a negative stockholders' equity, which is concerning. The debt-to-equity ratio is not meaningful due to negative equity, and the equity ratio is negative, indicating liabilities exceed assets significantly. This highlights a high leverage risk and financial instability.

Cash Flow

Operating cash flow is negative, showing the company is not generating enough cash from operations. Free cash flow is also negative, although there was an improvement in financing cash flow. The free cash flow to net income ratio is unfavorable, pointing to poor cash conversion from net income.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.01M	7.67K	89.16K	213.84K	48.27K	122.62K
Gross Profit	340.47K	6.00K	53.17K	198.56K	42.39K	26.67K
EBITDA	-2.91M	-3.59M	-2.68M	-3.15M	-4.48M	-2.83M
Net Income	-4.05M	-5.11M	-3.77M	-4.37M	-5.80M	-4.01M
Balance Sheet
Total Assets	7.53M	385.94K	388.89K	766.59K	819.98K	1.83M
Cash, Cash Equivalents and Short-Term Investments	287.69K	88.03K	65.22K	68.61K	85.84K	592.05K
Total Debt	2.78M	2.81M	1.81M	1.68M	1.77M	955.59K
Total Liabilities	20.30M	12.74M	10.34M	8.97M	7.78M	6.04M
Stockholders Equity	-12.76M	-12.12M	-9.82M	-8.08M	-6.84M	-4.09M
Cash Flow
Free Cash Flow	-1.70M	-1.10M	-1.85M	-2.04M	-3.59M	-2.16M
Operating Cash Flow	-1.70M	-1.10M	-1.85M	-2.04M	-3.54M	-2.15M
Investing Cash Flow	0.00	0.00	0.00	0.00	-50.00K	-9.23K
Financing Cash Flow	1.99M	1.12M	1.85M	2.02M	3.08M	107.30K

BioCorRx Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.40
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BICX, the sentiment is Negative. The current price of 0.4 is above the 20-day moving average (MA) of 0.36, below the 50-day MA of 0.40, and above the 200-day MA of 0.37, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 43.98 is Neutral, neither overbought nor oversold. The STOCH value of 52.38 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BICX.

BioCorRx Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
AMS	51 Neutral	$13.81M	-6.17	-8.75%	―	17.84%	-156.13%
TOI	47 Neutral	$340.40M	―	-3407.86%	―	21.67%	16.74%
CMPS	47 Neutral	$595.21M	―	-205.19%	―	―	-21.62%
CCEL	44 Neutral	$29.97M	―	―	10.67%	-0.29%	94.56%
CCM	38 Underperform	$18.45M	-0.80	―	―	-22.38%	56.66%
BICX	28 Underperform	$8.29M	-0.63	―	―	3464.86%	38.01%